Research and Markets has announced the addition of the "Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016" report to their offering.

The report provides comprehensive information on the Interleukin 12 Receptor (IL12R) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Interleukin 12 Receptor (IL12R) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Interleukin 12 Receptor Overview
  3. Therapeutics Development
  4. Pipeline Products for Interleukin 12 Receptor - Overview
  5. Pipeline Products for Interleukin 12 Receptor - Comparative Analysis
  6. Interleukin 12 Receptor - Therapeutics under Development by Companies
  7. Interleukin 12 Receptor - Therapeutics under Investigation by Universities/Institutes
  8. Interleukin 12 Receptor Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Interleukin 12 Receptor - Products under Development by Companies
  13. Interleukin 12 Receptor - Products under Investigation by Universities/Institutes
  14. Interleukin 12 Receptor - Companies Involved in Therapeutics Development

- Eli Lilly and Company

- Mallinckrodt Plc

- Merck KGaA

- Neumedicines Inc

For more information about this report visit http://www.researchandmarkets.com/research/644kdb/interleukin_12